Nessuna offerta aperta al momento.
WuXi Biologics, a biopharmaceutical company, is considering selling its U.S. facilities, as reported by BioSpace. The decision comes amid concerns over the BIOSECURE Act, which could restrict operations of Chinese companies in the U.S.
www.biospace.com